NUCLEA BIOTECHNOLOGIES ACQUIRES TISSUE MICROARRAY PATENTS
Former Clinomics patents had been assigned to Laurus Master Fund, Ltd
Pittsfield – Worcester, MA -- Nuclea Biotechnologies, Inc. today acquired a portfolio containing six patents and applications related to tissue microarrays that had previously belonged to Clinomics Biosciences. Nuclea purchased the Clinomics Patent Portfolio from Laurus Master Fund, Ltd, a division of New York based Laurus Capital Management, which had been assigned the patents. Patrick Muraca, president & CEO of Nuclea and formerly president & chief operating officer of Clinomics, is the inventor of all technologies in the portfolio.
“We believe these patents will allow Nuclea to expand our product offering and drive significant licensing revenue for the company,” Muraca said. “The tissue microarray technologies contained in this portfolio are very useful in specimen analysis, and we are eager to integrate them into our research.”
Nuclea acquired the portfolio for an undisclosed fee. The patents have not been maintained since being assigned to Laurus nearly seven years ago, but Nuclea plans to petition the USPTO to revive them immediately.
The portfolio includes:
- US Design Patent No. D473,648 S
- US Patent No. 6,716,619 B1
- US Patent No. 6,582,967 B2
- US Patent No. 6,534,307 B1
- US Serial No. 09/888,362
- US Serial No. 09/781,016
Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts with additional operations in Worcester, Massachusetts. Nuclea has developed and is commercializing eleven unique diagnostic tests for colon, breast, leukemia, lung, prostate cancer and most recently diabetes. Nuclea also performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.